Justin Kim
Stock Analyst at Oppenheimer
(1.53)
# 3,551
Out of 5,143 analysts
38
Total ratings
40%
Success rate
-5.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Maintains: Outperform | $44 → $50 | $27.50 | +81.82% | 5 | Dec 4, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $17 → $16 | $6.32 | +153.16% | 2 | Aug 15, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $65 → $40 | $20.95 | +90.93% | 6 | Nov 6, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $107 → $106 | $63.04 | +68.15% | 5 | May 9, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Outperform | $85 → $87 | $35.25 | +146.81% | 5 | Feb 29, 2024 | |
| VERA Vera Therapeutics | Initiates: Outperform | $26 | $45.77 | -43.19% | 1 | Jan 25, 2024 | |
| ALDX Aldeyra Therapeutics | Downgrades: Perform | n/a | $4.99 | - | 2 | Oct 17, 2023 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Perform | n/a | $14.78 | - | 6 | Nov 4, 2022 | |
| BCRX BioCryst Pharmaceuticals | Downgrades: Perform | n/a | $6.72 | - | 5 | Aug 8, 2022 | |
| IONS Ionis Pharmaceuticals | Assumes: Outperform | $59 | $79.44 | -25.73% | 1 | Jul 18, 2022 |
Pharvaris
Dec 4, 2025
Maintains: Outperform
Price Target: $44 → $50
Current: $27.50
Upside: +81.82%
Zura Bio
Aug 15, 2025
Maintains: Outperform
Price Target: $17 → $16
Current: $6.32
Upside: +153.16%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $65 → $40
Current: $20.95
Upside: +90.93%
Cytokinetics
May 9, 2024
Maintains: Outperform
Price Target: $107 → $106
Current: $63.04
Upside: +68.15%
Immunocore Holdings
Feb 29, 2024
Reiterates: Outperform
Price Target: $85 → $87
Current: $35.25
Upside: +146.81%
Vera Therapeutics
Jan 25, 2024
Initiates: Outperform
Price Target: $26
Current: $45.77
Upside: -43.19%
Aldeyra Therapeutics
Oct 17, 2023
Downgrades: Perform
Price Target: n/a
Current: $4.99
Upside: -
Aurinia Pharmaceuticals
Nov 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $14.78
Upside: -
BioCryst Pharmaceuticals
Aug 8, 2022
Downgrades: Perform
Price Target: n/a
Current: $6.72
Upside: -
Ionis Pharmaceuticals
Jul 18, 2022
Assumes: Outperform
Price Target: $59
Current: $79.44
Upside: -25.73%